Candel Therapeutics Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 0/6

Candel Therapeutics şirketinin toplam hissedar öz sermayesi $-10.0M ve toplam borcu $17.3M olup, bu da borç-öz sermaye oranını -173.7% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $26.5M ve $36.5M dir.

Anahtar bilgiler

-173.7%

Borç/özkaynak oranı

US$17.32m

Borç

Faiz karşılama oranı	n/a
Nakit	US$21.45m
Eşitlik	-US$9.97m
Toplam yükümlülükler	US$36.46m
Toplam varlıklar	US$26.49m

Son finansal sağlık güncellemeleri

Recent updates

Candel Therapeutics: Innovative Cancer Therapies, But Short Cash Runway

Jul 01

Candel Therapeutics: CAN-2409 May Go Beyond Scope Of Targeting Pancreatic Cancer

Apr 15

Candel gets European orphan drug designation for brain, spinal cord tumor treatment

Sep 15

Candel Therapeutics appoints CFO, chief medical officer

Sep 07

Candel Therapeutics: Next-Generation Oncolytic Viral Immunotherapies

Oct 21

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: CADL negatif hissedar özkaynağı var; bu, kısa vadeli varlıkların kısa vadeli yükümlülükleri karşılamamasından daha ciddi bir durumdur.

Uzun Vadeli Yükümlülükler: CADL şirketinin negatif özkaynağı bulunmaktadır; bu, kısa vadeli varlıkların uzun vadeli yükümlülükleri karşılamamasından daha ciddi bir durumdur.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: CADL negatif hissedar özkaynağı var ki bu yüksek borç seviyesinden daha ciddi bir durumdur.

Borcun Azaltılması: CADL 'in negatif özkaynağı var, dolayısıyla borcunun zaman içinde azalıp azalmadığını kontrol etmemize gerek yok.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: CADL şirketinin mevcut serbest nakit akışına göre bir yıldan az nakit akışı süresi bulunmaktadır.

Tahmini Nakit Akışı: CADL un, serbest nakit akışı her yıl % 26.2 oranında tarihi oranda azalmaya devam ederse bir yıldan az nakit akışı süresi vardır

Candel Therapeutics Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 0/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Candel Therapeutics Receives Non-Compliance Notice from Nasdaq

Candel Therapeutics Receives Non-Compliance Notice from Nasdaq

Recent updates

Candel Therapeutics: Innovative Cancer Therapies, But Short Cash Runway

Candel Therapeutics, Inc., Annual General Meeting, Jun 26, 2024

Candel Therapeutics Reports Prolonged Overall Survival in Phase 2 Clinical Trial of Can-2409 for Advanced Non-Small Cell Lung Cancer in Patients Non-Responsive to Immune Checkpoint Inhibitor Treatment At 2024 Asco Annual Meeting

Candel Therapeutics: CAN-2409 May Go Beyond Scope Of Targeting Pancreatic Cancer

Candel Therapeutics Presents Preclinical Data At Aacr on Immunotherapy Candidate for Induction of Tertiary Lymphoid Structures in Solid Tumors

Candel Therapeutics, Inc. Announces Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer

New major risk - Share price stability

Candel Therapeutics, Inc Announces Oral Presentation During the 5th Glioblastoma Drug Development Summit with Update on Phase 1b Clinical Trial of CAN-3110 in Recurrent High-Grade Glioma

Candel Therapeutics, Inc. Announces an Upcoming Presentation at the AACR Annual Meeting Unveiling New Cancer Immunotherapy Candidate

Candel Therapeutics, Inc.'s CAN-3110 Receives FDA Fast Track Designation for Treatment of Recurrent High-Grade Glioma

Candel Therapeutics, Inc. Announces Chief Financial Officer Changes

Candel Therapeutics, Inc. Receives FDA Fast Track Designation for CAN-2409 in Pancreatic Cancer

Candel Therapeutics Receives Non-Compliance Notice from Nasdaq

Candel Therapeutics Receives Non-Compliance Notice from Nasdaq

Third quarter 2023 earnings released: US$0.29 loss per share (vs US$0.30 loss in 3Q 2022)

New major risk - Share price stability

Candel Therapeutics, Inc. Announces Initial Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer

Candel Therapeutics, Inc. Announces Nature Publication Showing Extended Survival Associated with Immune Activation in Patients with Recurrent High-Grade Glioma Treated with CAN-3110

Candel Therapeutics, Inc. Announces Nature Publication Showing Extended Survival Associated with Immune Activation in Patients with Recurrent High-Grade Glioma Treated with CAN-3110

Candel Therapeutics, Inc. Reports Encouraging Initial Survival Data from Phase 2 Clinical Trial of CAN-2409 in Non-Small Cell Lung Cancer

Price target increased by 8.6% to US$9.50

First half 2023 earnings released: US$0.64 loss per share (vs US$0.17 loss in 1H 2022)

New major risk - Financial position

New major risk - Share price stability

Candel Therapeutics, Inc. Appoints Nicoletta Loggia to the Board of Directors

Candel Therapeutics, Inc., Annual General Meeting, Jun 28, 2023

Candel Therapeutics Announces New Data from Ongoing Phase 1 Clinical Trial of Can-3110 in Recurrent High-Grade Glioma At the American Society of Gene & Cell Therapy 26Th Annual Meeting

Price target decreased by 17% to US$7.25

First quarter 2023 earnings released: US$0.30 loss per share (vs US$0.03 loss in 1Q 2022)

Full year 2022 earnings released: US$0.65 loss per share (vs US$1.91 loss in FY 2021)

Independent Director recently bought US$73k worth of stock

Consensus forecasts updated

Price target decreased to US$11.60

Candel Therapeutics, Inc. R&D Day Presentations Spotlight Its Advanced Pipeline and Capabilities to Develop Novel Viral Immunotherapies for Patients with Cancer

Candel Therapeutics Announces Oral Presentation of Updated Data from Its Phase 1 Clinical Trial of Can-3110 in 41 Patients with Recurrent High-Grade Glioma At the Society for Neuro-Oncology 27Th Annual Meeting

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Candel Therapeutics Announces Late-Breaking Oral Presentation at SITC Annual Meeting with Data on CAN-2409 in Combination with Nivolumab in a Phase 1 Mechanistic Clinical Trial in Patients with High-Grade Glioma

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Candel gets European orphan drug designation for brain, spinal cord tumor treatment

Candel Therapeutics Announces Jason A. Amello as Chief Financial Officer, Effective September 21, 2022

Candel Therapeutics appoints CFO, chief medical officer

Candel Therapeutics, Inc., Annual General Meeting, Oct 13, 2022

Consensus forecasts updated

Consensus forecasts updated

Less than half of directors are independent

First half 2022 earnings released

Candel Therapeutics, Inc. Announces Executive Changes

Candel Therapeutics, Inc.(NasdaqGM:CADL) dropped from Russell Microcap Value Index

Candel Therapeutics, Inc. Releases Initial Data on CAN-2409 in A Phase 2 Clinical Trial Showing Cytotoxic T Cell Response and Disease Control in Patients with Non-Small Cell Lung Cancer

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Consensus forecasts updated

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Candel Therapeutics, Inc Expects to Present Initial Data from an Ongoing Phase 2 Clinical Trial of CAN-2409

Candel Therapeutics, Inc. Appoints Seshu Tyagarajan as Chief Technical and Development Officer

Candel Therapeutics, Inc. Appoints Seshu Tyagarajan as Chief Technical and Development Officer

Candel Therapeutics, Inc. Appoints Dr. Francesca Barone as Chief Scientific Officer

Candel Therapeutics, Inc. Removes Estuardo Aguilar-Cordova and Laura Aguilar from the Board

Candel Therapeutics, Inc. and Partnership for Accelerating Cancer Therapies to Collaborate on Lung Cancer Trial for CAN-2409

Third quarter 2021 earnings released: US$0.69 loss per share

Candel Therapeutics: Next-Generation Oncolytic Viral Immunotherapies

Chairman recently bought US$411k worth of stock

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin